CCR4 and adult T-cell leukemia/lymphoma: Since the expression of CCR4 at high levels on malignant T cells provided an attractive therapeutic target for ATLL and CTCLs [95,131], the company first generated a chimeric and defucosylated anti-CCR4 termed KM2760 from KM2160 and confirmed that KM2760 exhibited a much higher ADCC against CCR4-expressing T cell lines in vitro and higher antitumor activities in transplanted mouse models than the highly fucosylated but otherwise identical KM3060 [144].